Aptus Study Team leads AstraZeneca AZD5363 BEECH study to recruitment milestone

Led by a 5 strong clinical operations team from Aptus Clinical, the AZD5363 ‘BEECH’ study recently completed recruitment with a total of 110 patients randomised to this Phase 2b study examining the safety, tolerability and efficacy of AZD5363 when combined with Paclitaxel in Breast Cancer patients which is being conducted in 11 counties around the world. The team achieved this milestone through an integrated approach with AZ Marketing Companies and working closely with other AZ service delivery partners. Emma Outhwaite, Aptus Clinical Project Manager and Clinical Study Team Leader said “We are delighted that the hard work everyone has put into the study, from the investigator sites, AZ marketing companies and the wider study team, has resulted in us achieving this key study milestone. We look forward to maintaining this successful partnership through to completion of this important study for breast cancer patients.